H.C. Wainwright raised the firm’s price target on Enliven (ELVN) to $48 from $40 and keeps a Buy rating on the shares after the company presented updated results from the Phase 1a/1b ENABLE trial at EHA 2025. Following the presentation at the medical meeting, the firm contends that ELVN-001 could become “the go-to agent” in chronic myelogenous leukemia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer?
- Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study
- Enliven Therapeutics Appoints New Directors at Annual Meeting
- Short Report: Short interest in residential solar heats up again
- Enliven price target raised to $52 from $40 at Baird